CymaBay's RESPONSE Phase 3 Data Evaluating Seladelpar For Primary Biliary Cholangitis To Be Featured In An Oral Late-Breaking Presentation At The Liver Meeting 2023
Portfolio Pulse from Benzinga Newsdesk
CymaBay Therapeutics (NASDAQ:CBAY) announced that results from the RESPONSE Phase 3 study of seladelpar in patients with primary biliary cholangitis (PBC) will be presented at The Liver Meeting® of the American Association for the Study of Liver Diseases (AASLD). Seladelpar is a potent, selective, orally active delpar or PPARδ agonist, in development for the treatment of adult patients with PBC. The company looks forward to sharing the results, which is an important step forward in obtaining regulatory review and potentially marketing authorization.
October 18, 2023 | 12:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
CymaBay Therapeutics is set to present results from the RESPONSE Phase 3 study of seladelpar, a treatment for primary biliary cholangitis. This could potentially lead to regulatory review and marketing authorization, which would be a significant milestone for the company.
The announcement of the presentation of Phase 3 study results is a positive development for CymaBay Therapeutics. If the results are positive, it could lead to regulatory review and marketing authorization, which would be a significant milestone for the company and could potentially boost its stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100